Prevention of Aromatase Inhibitor–Induced Bone Loss Using Risedronate: The SABRE Trial

Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer

(2009) Michael Gnant et al.   NEW ENGLAND JOURNAL OF MEDICINE

Guidance for the management of breast cancer treatment-induced bone loss: A consensus position statement from a UK Expert Group

(2008) David M. Reid et al.   CANCER TREATMENT REVIEWS

The Antiresorptive Effects of a Single Dose of Zoledronate Persist for Two Years: A Randomized, Placebo-Controlled Trial in Osteopenic Postmenopausal Women

(2008) Andrew Grey et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer

(2008) Georgiana K. Ellis et al.   JOURNAL OF CLINICAL ONCOLOGY

Advances in Adjuvant Endocrine Therapy for Postmenopausal Women

(2008) Nancy U. Lin et al.   JOURNAL OF CLINICAL ONCOLOGY

Risedronate Prevents Bone Loss in Breast Cancer Survivors: A 2-Year, Randomized, Double-Blind, Placebo-Controlled Clinical Trial

(2008) Susan L. Greenspan et al.   JOURNAL OF CLINICAL ONCOLOGY

Ten-Year Follow-Up of 3 Years of Oral Adjuvant Clodronate Therapy Shows Significant Prevention of Osteoporosis in Early-Stage Breast Cancer

(2008) Tiina Saarto et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of Anastrozole on Bone Mineral Density: 5-Year Results From the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230

(2008) Richard Eastell et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer Treatment–Induced Bone Loss in Breast and Prostate Cancer

(2008) Fred Saad et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

(2008)   LANCET ONCOLOGY

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy

(2008) Michael Gnant et al.   LANCET ONCOLOGY

Integrated Analysis of Zoledronic Acid for Prevention of Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole

(2008) A. Brufsky et al.   ONCOLOGIST